9th Annual Biomarkers Congress
Evolving Approaches to Early Stage Drug Discovery (Z2)
Snowbird Resort

Sandy, Utah
http://keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1093
   Deadlines
   ---------

     *  Abstract Deadline:
       2nd December 2010

     *  Registration Deadline:
       3rd February 2011


   Speakers
   --------

     *  Albert B. Seymour, Pfizer Global Research and Development, USA

     *  Padraic G. Fallon, Trinity College, Ireland

     *  Jose-Carlos Gutierrez-Ramos, Pfizer, Inc, USA

     *  James E. Audia?, Eli Lilly and Company, USA

     *  Robert Gould, Epizyme, Inc., USA

     *  Miles Congreve, Heptares Therapeutics Ltd, United Kingdom

     *  Linda Brady, National Institute of Mental Health, National
       Institutes of Health, USA

     *  Antonio Alcami, Centro de Biologia Molecular Severo Ochoa, Spain

     *  Grant McFadden, University of Florida, USA

     *  William Harnett, Strathclyde Institute for Biomedical Sciences,
       United Kingdom

     *  Short Talk(s) to be Chosen from Abstracts,

     *  Bryan Roth, University of North Carolina, Chapel Hill, USA

     *  Daryl R. Sauer, Abbott Laboratories, USA

     *  Speaker to be Announced,

     *  Anne Cooke, University of Cambridge, United Kingdom

     * 

     *  Ana Marisa Chudzinski-Tavassi, Instituto Butantan, Brazil

     *  Cathryn Nagler, University of Chicago, USA

     * 

     *  Sarkis K. Mazmanian, California Institute of Technology, USA

     *  Dennis C. Liotta, Emory University, USA

     *  P. Jeffrey Conn, Vanderbilt University School of Medicine, USA

     *  Julian Blagg, Institute of Cancer Research, United Kingdom

     *  James A. Wells, University of California, San Francisco, USA

     *  Alexandra R. Lucas, University of Florida, USA

     *  Amanda E.I. Proudfoot Fichard, Merck Serono Geneva Research
       Centre, Switzerland

     *  Padraic G. Fallon, Trinity College, Ireland

     *  Wynne Weston-Davies, Polymed Development Ltd, United Kingdom

     *  Cyrille Sur?, Merck & Co., Inc., USA

     *  Jacob M. Hooker, Athinoula A. Martinos Center for Biomedical
       Imaging, USA

     *  Javier Sanz, Mount Sinai School of Medicine, USA

     *  Jos van Strijp, University Medical Center Utrecht, Netherlands

     *  Daved Fremont, Washington University School of Medicine, USA

     *  Tracy M. Handel, University of California, San Diego, USA

     *  Short Talk to be Chosen from Abstracts,

     *  H. Alex Brown, Vanderbilt University, USA

     *  Dinah Sah, Alnylam Pharmaceuticals Inc., USA

     *  Mark Layton?, Merck Research Laboratories, USA

     *  Craig W. Lindsley, Vanderbilt University, USA

     *  Victor Nizet, UCSD School of Medicine, USA

     *  Kate A. Fitzgerald, University of Massachusetts Medical School,
       USA

     *  Luke A.J. O’Neill, Trinity College Dublin, Ireland

     *  Speaker to be Announced,

     *  Short Talk(s) to be Chosen from Abstracts,

     *  Alan Palkowitz?, Eli Lilly and Company, USA

     *  Speaker to be Announced,

     *  Dimitri Grigoriadis, Neurocrine Biosciences, Inc., USA

     *  Antonio Alcami, Centro de Biologia Molecular Severo Ochoa, Spain

     *  Michael K. Richardson, Leiden University, Netherlands

     * 

     * 

     *  Colin Macaulay, Viron Therapeutics Inc., Canada

     *  Reto Stöcklin, Atheris Laboratories, Switzerland

     *  Short Talk to be Chosen from Abstracts,

   This meeting will cover multiple aspects of the challenges and
   opportunities facing drug discovery scientists. These challenges
   include: 1) diverse approaches to early stage discovery in a resource
   constrained environment, 2) evolution of preclinical drug discovery in
   academia, 3) evolution of drug leads/target validation from the NIH (
   MLPCN ), 4) funding early stage/risky programs, 5) external licensing
   of programs and 6) advances in biomarkers/imaging to enable target
   selection and rapid go/no go decisions. The meeting goals are to bring
   together experts in all of these areas, present findings/opinions and
   initiate dialog on these topics. This would be the first meeting to
   bring together drug discovery scientists form big Pharma, biotech,
   academia, the MLPCN and Foundations

Schedule of Presentations:

Sunday, April 3, 2011
15:00:00 Registration
18:15:00 Refreshments
19:10:00 Session | Anti-Inflammatory Drugs (Z1)
19:15:00 Anti-Inflammatory Drugs (Z1) | Welcome and Keynote Address Padraic G. Fallon
19:15:00 Welcome and Keynote Address
20:00:00 Human Genetic Approaches to Biotherapeutics | Target ID to Patient Enrichment Albert B. Seymour
20:00:00 Anti-Inflammatory Drugs (Z1) | Anti-Inflammatory Drugs: The Path from Discovery to the Clinic Jose-Carlos Gutierrez-Ramos
Monday, April 4, 2011
07:00:00 Breakfast
08:00:00 Evolving Strategies for Screening and Early Lead Identification
08:00:00 Session | Anti-Inflammatory Drugs (Z1)
08:30:00 PD2: New Collaborative Models for Early Stage Drug Discovery Timothy A. Grese
08:30:00 Anti-Inflammatory Drugs (Z1) | Immune Modulating Molecules from Pathogens
09:00:00 Histone Methyl Transferase Inhibitors: Targeted Therapeutics for Targeted Patients Robert Gould
09:00:00 Anti-Inflammatory Drugs (Z1) | Therapeutic Exploitation of Viral Chemokine-Modulators Antonio Alcami
09:20:00 Coffee Break
09:30:00 Fragment-Based Screening Approaches to GPCR Targets Miles Congreve
09:45:00 Probe Development within the Molecular Libraries Probe Production Centers Network (MLPCN): Leads for Drug Development from Previously Intractable Targets Linda Brady
09:45:00 Anti-Inflammatory Drugs (Z1) | When the Bug is the Drug: Exploiting Poxviruses for Oncolytic Virotherapy Grant McFadden
10:00:00 Anti-Inflammatory Drugs (Z1) | The Path from a Pathogen Molecule to Synthetic Anti-Inflammatory Mimetics: The ES-62 Story William Harnett
10:30:00 Anti-Inflammatory Drugs (Z1) | Short Talk(s) to be Chosen from Abstracts
11:00:00 Poster Setup
11:00:00 On Own for Lunch and Recreation
13:00:00 Poster Viewing
16:30:00 Coffee Available
16:55:00 Session | Anti-Inflammatory Drugs (Z1)
17:00:00 Anti-Inflammatory Drugs (Z1) | Pathogen Modulators of Immune-Mediated Diseases
17:00:00 Novel Approaches and Technology for Early Stage Drug Discovery
17:30:00 Anti-Inflammatory Drugs (Z1) | Modulation of autoimmunity by pathogen derived molecules Anne Cooke
17:30:00 Identifying new molecular targets for known drugs Bryan Roth
18:00:00 Anti-Inflammatory Drugs (Z1) | Novel Drugs from Ticks for Cancer Ana Marisa Chudzinski-Tavassi
18:00:00 Chemical and Separation Technologies to Accelerate the Hit-to-Lead Phase: Case Studies Daryl R. Sauer
18:30:00 Anti-Inflammatory Drugs (Z1) | The Use of Enteric Infections for Treating Allergic Diseases Cathryn Nagler
18:45:00 Anti-Inflammatory Drugs (Z1) | Exploiting Commensal Immune Modulation for New Drugs Sarkis K. Mazmanian
19:00:00 Social Hour w/ Lite Bites
19:30:00 Poster Session 1
Tuesday, April 5, 2011
07:00:00 Breakfast
08:00:00 Drug Discovery in Academia
08:00:00 Session | Anti-Inflammatory Drugs (Z1)
08:05:00 Anti-Inflammatory Drugs (Z1) | Clinical Perspective/Development
08:30:00 The Role of CXCR4 Modulators in Controlling HIV Entry, Inflammation and Certain Types of Cancer Dennis C. Liotta
08:30:00 Anti-Inflammatory Drugs (Z1) | Viral Bugs Make Great Drugs
09:00:00 Partnering with Big Pharma to Develop mGluR Allosteric Modulators for CNS Disorders: From HTS to Clinical Candidates P. Jeffrey Conn
09:00:00 Anti-Inflammatory Drugs (Z1) | Pathogen-Derived and Anti-Inflammatory Drugs Amanda E.I. Proudfoot Fichard
09:20:00 Coffee Break
09:45:00 Novel Cancer Therapeutics Developed through Academic-Industrial Partnerships Julian Blagg
10:00:00 Turning Enzymes on with Small Molecules Jim Wells
10:00:00 Anti-Inflammatory Drugs (Z1) | Who needs a drug for allergies when a bug will do? Padraic G. Fallon
10:30:00 Anti-Inflammatory Drugs (Z1) | Clinical Trials of Arthropod-Derived Molecules Wynne Weston-Davies
11:00:00 Poster Setup
11:00:00 On Own for Lunch and Recreation
13:00:00 Poster Viewing
14:30:00 Workshop
15:00:00 Short Talks to be Chosen from Abstracts
16:30:00 Coffee Available
16:55:00 Session | Anti-Inflammatory Drugs (Z1)
17:00:00 Imaging and Biomarkers in Early Stage Discovery
17:30:00 Anti-Inflammatory Drugs (Z1) | Anti-Inflammatory Drugs from Staphylococcus Aureus Jos van Strijp
17:30:00 Small Molecule Biomarkers in Drug Discovery: Optical and PET Imaging Approaches Cyrille Sur
18:00:00 Advances in Carbon-11 Chemistry for Use in Positron Emission Tomography Jacob M. Hooker
18:00:00 Anti-Inflammatory Drugs (Z1) | Structural Mechanisms of Viral Inflammation Modulators Daved Fremont
18:30:00 New Approaches for Imaging of Atherosclerotic Cardiovascular Disease Javier Sanz
18:30:00 Anti-Inflammatory Drugs (Z1) | Computational Structural Analysis for Design of Pathogen-Derived Therapeutics Tracy M. Handel
18:45:00 Anti-Inflammatory Drugs (Z1) | Short Talk to be Chosen from Abstracts
19:00:00 Social Hour w/ Lite Bites
19:30:00 Poster Session 2
Wednesday, April 6, 2011
07:00:00 Breakfast
07:55:00 Session | Anti-Inflammatory Drugs (Z1)
08:00:00 Anti-Inflammatory Drugs (Z1) | Pathogen Modulation of Inflammatory Signaling
08:00:00 Emerging Targets and Approaches in Drug Discovery
08:30:00 Anti-Inflammatory Drugs (Z1) | Probing Bacterial-Phagocyte Interactions for Novel Infectious Disease (and Anti-Inflammatory?) Therapeutics Victor Nizet
08:30:00 Phospholipase D: Discovery and Development of Isoform Selective PLD Inhibitors for the Treatment of Cancer H Alex Brown
09:00:00 siRNA Therapeutics: Overview and Clinical Trial Update
09:00:00 Anti-Inflammatory Drugs (Z1) | Sensing from within: cytosolic sensors and anti-microbial defenses Kate A. Fitzgerald
09:20:00 Coffee Break
09:45:00 Anti-Inflammatory Drugs (Z1) | Exploiting Pathogen Subversion of Immunity for New Drugs Luke A.J. O'Neill
09:45:00 Allosteric Akt Kinase Inhibitors: Discovery Overview and Clinical Update Mark Layton
10:00:00 Allosteric Modulation of Muscarinic Receptors for Treatment of Schizophrenia and Alzheimer's Disease Prof. Craig Lindsley
10:00:00 Anti-Inflammatory Drugs (Z1) | Possible Novel Drugs from Arthropod Venoms Maria Elena Lima
10:30:00 Anti-Inflammatory Drugs (Z1) | Short Talk(s) to be Chosen from Abstracts
11:00:00 On Own for Lunch and Recreation
16:30:00 Coffee Available
16:55:00 Session | Anti-Inflammatory Drugs (Z1)
17:00:00 Anti-Inflammatory Drugs (Z1) | Screening Strategies/Technologies- Recent Advances Antonio Alcami
17:00:00 Evolving Role of Big Pharma and Biotech
17:30:00 Bruton’s Tyrosine Kinase from Bench to Bedside: Covalently Silencing B Cells with AVL-292 Juswinder Singh
17:30:00 Anti-Inflammatory Drugs (Z1) | Zebrafish in the Drug Development Pipeline Michael K. Richardson
18:00:00 Anti-Inflammatory Drugs (Z1) | From Pathogen Immunomodulators to Novel Drugs Colin Macaulay
18:00:00 Innovation and the Future of Novel Drug Discovery in Biotech Dimitri Grigoriadis
18:30:00 Anti-Inflammatory Drugs (Z1) | Venomics: Animal Venoms as Drug Discovery Platforms Reto Stöcklin
18:45:00 Anti-Inflammatory Drugs (Z1) | Short Talk to be Chosen from Abstracts
19:00:00 Social Hour w/ Lite Bites
20:00:00 Entertainment
Thursday, April 7, 2011
09:00:00 Departure
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.